These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 18408926)

  • 1. Molecular mechanisms of MHC class I abnormalities and APM components in human tumors.
    Seliger B
    Cancer Immunol Immunother; 2008 Nov; 57(11):1719-26. PubMed ID: 18408926
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different regulation of MHC class I antigen processing components in human tumors.
    Seliger B
    J Immunotoxicol; 2008 Oct; 5(4):361-7. PubMed ID: 19404870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of genetic variations on MHC class I antigen-processing genes in human cancer and viral-mediated diseases.
    D'Alicandro V; Romania P; Melaiu O; Fruci D
    Mol Immunol; 2019 Sep; 113():11-15. PubMed ID: 29625843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation.
    Dhatchinamoorthy K; Colbert JD; Rock KL
    Front Immunol; 2021; 12():636568. PubMed ID: 33767702
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NLRC5/MHC class I transactivator is a target for immune evasion in cancer.
    Yoshihama S; Roszik J; Downs I; Meissner TB; Vijayan S; Chapuy B; Sidiq T; Shipp MA; Lizee GA; Kobayashi KS
    Proc Natl Acad Sci U S A; 2016 May; 113(21):5999-6004. PubMed ID: 27162338
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma.
    Ritz U; Momburg F; Pilch H; Huber C; Maeurer MJ; Seliger B
    Int J Oncol; 2001 Dec; 19(6):1211-20. PubMed ID: 11713591
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of classical and non-classical HLA class I antigens in human tumors.
    Bukur J; Jasinski S; Seliger B
    Semin Cancer Biol; 2012 Aug; 22(4):350-8. PubMed ID: 22465194
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IRF1 and NF-kB restore MHC class I-restricted tumor antigen processing and presentation to cytotoxic T cells in aggressive neuroblastoma.
    Lorenzi S; Forloni M; Cifaldi L; Antonucci C; Citti A; Boldrini R; Pezzullo M; Castellano A; Russo V; van der Bruggen P; Giacomini P; Locatelli F; Fruci D
    PLoS One; 2012; 7(10):e46928. PubMed ID: 23071666
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin.
    Seliger B; Wollscheid U; Momburg F; Blankenstein T; Huber C
    Tissue Antigens; 2000 Oct; 56(4):327-36. PubMed ID: 11098932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes.
    Seliger B; Harders C; Wollscheid U; Staege MS; Reske-Kunz AB; Huber C
    Exp Hematol; 1996 Sep; 24(11):1275-9. PubMed ID: 8862437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing.
    Leclerc M; Mezquita L; Guillebot De Nerville G; Tihy I; Malenica I; Chouaib S; Mami-Chouaib F
    Front Immunol; 2019; 10():1505. PubMed ID: 31333652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alternative processing pathways for MHC class I-restricted epitope presentation to CD8+ cytotoxic T lymphocytes.
    Reimann J; Böhm W; Schirmbeck R
    Biol Chem Hoppe Seyler; 1994 Nov; 375(11):731-6. PubMed ID: 7535058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokines restore MHC class I complex formation and control antigen presentation in human cytomegalovirus-infected cells.
    Hengel H; Esslinger C; Pool J; Goulmy E; Koszinowski UH
    J Gen Virol; 1995 Dec; 76 ( Pt 12)():2987-97. PubMed ID: 8847504
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HLA Class I Antigen Processing Machinery Defects in Cancer Cells-Frequency, Functional Significance, and Clinical Relevance with Special Emphasis on Their Role in T Cell-Based Immunotherapy of Malignant Disease.
    Seliger B; Ferrone S
    Methods Mol Biol; 2020; 2055():325-350. PubMed ID: 31502159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The tumour suppressor Fhit positively regulates MHC class I expression on cancer cells.
    Romero I; Martinez M; Garrido C; Collado A; Algarra I; Garrido F; Garcia-Lora AM
    J Pathol; 2012 Jul; 227(3):367-79. PubMed ID: 22451343
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The link between MHC class I abnormalities of tumors, oncogenes, tumor suppressor genes, and transcription factors.
    Seliger B
    J Immunotoxicol; 2014 Oct; 11(4):308-10. PubMed ID: 24479372
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocytic Recycling of MHC Class I Molecules in Non-professional Antigen Presenting and Dendritic Cells.
    Montealegre S; van Endert PM
    Front Immunol; 2018; 9():3098. PubMed ID: 30666258
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coordinated downregulation of the antigen presentation machinery and HLA class I/beta2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer.
    Romero JM; Jiménez P; Cabrera T; Cózar JM; Pedrinaci S; Tallada M; Garrido F; Ruiz-Cabello F
    Int J Cancer; 2005 Feb; 113(4):605-10. PubMed ID: 15455355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MHC class I antigens, immune surveillance, and tumor immune escape.
    Garcia-Lora A; Algarra I; Garrido F
    J Cell Physiol; 2003 Jun; 195(3):346-55. PubMed ID: 12704644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of MHC class I antigen presentation by viral proteins.
    Früh K; Ahn K; Peterson PA
    J Mol Med (Berl); 1997 Jan; 75(1):18-27. PubMed ID: 9020380
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.